Claudio Jommi

Government, Health and Not for Profit

Biography

Latest publications

ROGNONI C., BERTOLANI A., JOMMI C. Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects Clinical Drug Investigation, 2021, vol.41, no. 4, pp.303-319
ARMENI P., BERTOLANI A., COSTA F., OTTO M., JOMMI C. Tetti alla farmaceutica e sostenibilità: il risultato è possibile, ma la strada è giusta? Sanità. Il Sole 24 ore, 23 March, 2021
ARMENI P., BORSOI L., FORNARO G., JOMMI C., COLOMBO N., COSTA F. Cost-Effectiveness and Net Monetary Benefit of olaparib Maintenance Therapy Versus No Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-Mutated Ovarian Cancer in the Italian National Health Service Clinical Therapeutics, 2020, vol.42, no. 7, pp.1192-1209
ARMENI P., BORSOI L., FORNARO G., JOMMI C., Grossi Francesco, COSTA F. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non–small Cell Lung Cancer in the Italian National Health Service Clinical Therapeutics, 2020, vol.42, no. 5, pp.830-847
JOMMI C., ARMENI P., BERTOLANI A., COSTA F., OTTO M. Il futuro della politica del farmaco in Italia: l’opinione degli stakeholder Sanità. Il Sole 24 ore, 1 April, 2020
JOMMI C., ARMENI P., COSTA F., BERTOLANI A., OTTO M. Implementation of Value-based Pricing for Medicines Clinical Therapeutics, 2020, vol.42, no. 1, pp.15-24

Grants & Honors

Management of funds for innovative medicines - MSD Oncology , 2020

Related Articles

Striking the right balance between value and price in pha...
Authors
Required time 6 min

Director

MIHMEP
Master of International Healthcare Management, Economics and Policy
Language ENGLISH
Total duration One year
Start date 26 Sep 2021